October 2, 2026
Frederick, MD – Jecho Laboratories, Inc. will present emerging clinical data from an open-label, multi-center Phase 1 study of JLM019, a CD80/PD-1 dual target Fc fusion protein, under evaluation for safety, tolerability, and preliminary efficacy in patients with advanced malignancies. Jecho will also present preclinical data from JLM070, a PD-L1-directed 4-1BB ligand fusion protein, as a next-generation immuno-oncology agent designed to overcome systemic toxicities from first generation 4-1BB antibodies and with a wider therapeutic window than second-generation conditionally activated bispecific antibodies.
The SITC meeting will be held November 4-8, 2026, in Phoenix, AZ.
Details of the presentations are below:
A Phase I Study to Evaluate the Safety and Tolerability of JLM019 Injection in patients with advanced malignancies
- Abstract Presentation Number: 564
- Session Time: Saturday, November 7
- Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4-6
- SITC link: TBD
A novel PD-L1-directed 4-1BB ligand fusion protein, JLM070, demonstrates potent antitumor activity and a favorable safety profile in preclinical models
- Abstract Presentation Number: 967
- Session Time: Friday, November 6
- Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4-6
- SITC link: TBD